Loading clinical trials...
Loading clinical trials...
Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'
Conditions
Interventions
bevacizumab [Avastin]
Oxaliplatin
+1 more
Locations
38
Italy
Bologna, Italy
Brescia, Italy
Cagliari, Italy
Cagliari, Italy
Caserta, Italy
Catanzaro, Italy
Start Date
February 1, 2008
Primary Completion Date
August 1, 2011
Completion Date
August 1, 2011
Last Updated
August 18, 2015
NCT06696768
NCT04704661
NCT05489211
NCT04657068
NCT06625775
NCT06607458
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions